tiprankstipranks
Trending News
More News >
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
US Market
Advertisement

NewAmsterdam Pharma Company (NAMS) AI Stock Analysis

Compare
229 Followers

Top Page

NAMS

NewAmsterdam Pharma Company

(NASDAQ:NAMS)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - 4o)
Rating:63Neutral
Price Target:
$27.00
▲(2.70% Upside)
NewAmsterdam Pharma's overall score is driven by strong corporate events and positive technical indicators. Financial performance is typical for a biotech firm with growth potential but current profitability challenges. Valuation is constrained by negative earnings, but the company's strategic advancements and market opportunities provide a positive outlook.
Positive Factors
Regulatory Milestone
EMA validation is a critical step towards commercialization in Europe, expanding market reach and enhancing competitive positioning in the cardiovascular treatment sector.
Clinical Trial Success
Successful trial results position NAMS as a leader in both cardiovascular and neurodegenerative disease treatment, potentially increasing market share and revenue.
Strategic Partnerships
The partnership with Menarini enhances distribution capabilities and operational efficiency, supporting long-term growth and market penetration.
Negative Factors
Profitability Challenges
Persistent operational losses due to high R&D costs can strain financial resources, delaying profitability and impacting long-term financial health.
Negative Cash Flow
Negative cash flow indicates ongoing cash burn, which may necessitate further capital raising, potentially diluting existing shareholders.
Volatile Revenue
Revenue volatility can complicate financial planning and investor confidence, impacting the company's ability to sustain long-term growth.

NewAmsterdam Pharma Company (NAMS) vs. SPDR S&P 500 ETF (SPY)

NewAmsterdam Pharma Company Business Overview & Revenue Model

Company DescriptionNewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
How the Company Makes MoneyNewAmsterdam Pharma generates revenue primarily through the commercialization of its pharmaceutical products, which are sold to healthcare providers, hospitals, and pharmacies. The company may also engage in strategic partnerships with larger pharmaceutical firms for joint development and marketing of its drug candidates, which can provide additional income through upfront payments and royalties on sales. Research grants and funding from government and private entities for clinical trials and product development may also contribute to its revenue. Additionally, licensing agreements for its intellectual property could serve as significant revenue streams, enhancing the company's financial stability.

NewAmsterdam Pharma Company Financial Statement Overview

Summary
NewAmsterdam Pharma exhibits typical biotech characteristics with high R&D expenses leading to operational losses. Revenue growth is promising, but profitability remains a challenge. The balance sheet is strong with low leverage, providing stability. Cash flows are negative, but capital raising efforts support liquidity.
Income Statement
45
Neutral
The company's revenue has shown significant volatility with periods of growth and decline. The gross profit margin is 100% due to no cost of goods sold, but the net profit margin is low due to high operating expenses. EBIT and EBITDA margins are negative, indicating operational challenges. Revenue growth from 2023 to 2024 is strong, but the company has not achieved profitability.
Balance Sheet
60
Neutral
The company maintains a strong equity position with an equity ratio of 87.6%, indicating low leverage. Debt-to-equity is minimal at 0.06, suggesting low financial risk. However, the company has reported consecutive net losses, impacting return on equity, which remains negative.
Cash Flow
55
Neutral
Operating cash flow is consistently negative, highlighting cash burn issues typical in the biotechnology industry. Free cash flow growth is negative, indicating increased outflows. However, ample financing cash flow suggests the company is able to raise capital successfully, mitigating immediate liquidity concerns.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue64.01M45.56M12.76M95.91M0.000.00
Gross Profit64.01M45.56M12.76M95.91M0.000.00
EBITDA-240.00M-241.49M-176.86M-3.31M-30.73M-5.43M
Net Income-165.72M-241.60M-176.94M-21.14M-36.71M-5.75M
Balance Sheet
Total Assets815.11M864.62M347.10M531.58M59.78M9.23M
Cash, Cash Equivalents and Short-Term Investments739.16M834.19M340.45M438.52M53.09M7.86M
Total Debt328.00K448.00K60.00K118.00K164.00K11.65M
Total Liabilities36.62M107.12M58.70M47.06M9.99M12.81M
Stockholders Equity778.50M757.50M288.39M484.52M49.79M-3.58M
Cash Flow
Free Cash Flow-124.30M-159.24M-141.24M7.96M-25.18M-5.98M
Operating Cash Flow-124.12M-158.56M-141.22M7.97M-25.16M-5.97M
Investing Cash Flow-218.53M-62.85M-24.00K715.00K-20.00K-13.00K
Financing Cash Flow466.61M659.51M8.91M375.18M68.99M11.32M

NewAmsterdam Pharma Company Technical Analysis

Technical Analysis Sentiment
Positive
Last Price26.29
Price Trends
50DMA
24.48
Positive
100DMA
21.87
Positive
200DMA
21.68
Positive
Market Momentum
MACD
0.62
Negative
RSI
55.41
Neutral
STOCH
82.06
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Positive. The current price of 26.29 is above the 20-day moving average (MA) of 25.64, above the 50-day MA of 24.48, and above the 200-day MA of 21.68, indicating a bullish trend. The MACD of 0.62 indicates Negative momentum. The RSI at 55.41 is Neutral, neither overbought nor oversold. The STOCH value of 82.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NAMS.

NewAmsterdam Pharma Company Risk Analysis

NewAmsterdam Pharma Company disclosed 91 risk factors in its most recent earnings report. NewAmsterdam Pharma Company reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

NewAmsterdam Pharma Company Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
2.67B863.990.97%56.18%
63
Neutral
$3.05B-28.43%
53
Neutral
2.99B-16.35-63.73%
48
Neutral
2.82B-10.31-29.45%
45
Neutral
2.69B-5.51-48.38%
37
Underperform
3.43B-15.13-70.28%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NAMS
NewAmsterdam Pharma Company
26.29
10.06
61.98%
VKTX
Viking Therapeutics
25.09
-36.54
-59.29%
XENE
Xenon
36.52
-2.13
-5.51%
SLNO
Soleno Therapeutics
62.72
13.59
27.66%
KNSA
Kiniksa Pharmaceuticals
35.51
10.51
42.04%
IMVT
Immunovant
15.67
-12.35
-44.08%

NewAmsterdam Pharma Company Corporate Events

Product-Related AnnouncementsPrivate Placements and FinancingBusiness Operations and Strategy
NewAmsterdam Pharma Highlights Progress in Obicetrapib Trials
Positive
Sep 2, 2025

On September 2, 2025, NewAmsterdam Pharma Company released an updated corporate investor presentation highlighting significant progress in its clinical trials for obicetrapib, a promising treatment for lowering LDL-C levels. The presentation detailed the company’s strategic plans, including securing funding for a potential U.S. commercial launch and expanding its workforce. The company’s trials have shown favorable results, indicating a substantial market opportunity, particularly in the U.S., where many patients are not meeting cholesterol goals with existing treatments.

Product-Related AnnouncementsRegulatory Filings and Compliance
NewAmsterdam Pharma’s EMA Validation for Obicetrapib
Positive
Aug 18, 2025

On August 18, 2025, NewAmsterdam Pharma announced that the European Medicines Agency has validated the Marketing Authorization Application for obicetrapib, both as a monotherapy and in combination with ezetimibe, for treating primary hypercholesterolemia and mixed dyslipidemia. This validation marks a significant step for NewAmsterdam, allowing the EMA to review pivotal Phase 3 trials, which demonstrated substantial LDL-C reductions. The company, in partnership with Menarini, aims to bring this novel treatment to Europe, potentially offering a new therapeutic option for patients not meeting LDL-C goals despite existing treatments.

Product-Related AnnouncementsBusiness Operations and Strategy
NewAmsterdam Pharma Signs Supply Agreement with Menarini
Neutral
Aug 15, 2025

On August 12, 2025, NewAmsterdam Pharma’s subsidiary entered into a Supply Agreement with A. Menarini International Licensing S.A. to supply obicetrapib monotherapy and combination drug products. The agreement outlines NewAmsterdam Pharma as the exclusive supplier initially, with plans to transfer manufacturing to Menarini or a third party, impacting the company’s operational dynamics and industry positioning.

Product-Related AnnouncementsBusiness Operations and Strategy
NewAmsterdam Pharma’s Promising Phase 3 Alzheimer’s Trial Results
Positive
Jul 30, 2025

On July 30, 2025, NewAmsterdam Pharma announced promising results from its Phase 3 BROADWAY clinical trial, which evaluated the effects of obicetrapib on Alzheimer’s disease biomarkers. The trial showed that obicetrapib significantly reduced levels of plasma p-tau217, a key biomarker of Alzheimer’s pathology, especially in ApoE4 carriers, a group at heightened risk for the disease. These findings suggest that obicetrapib could offer a novel approach to Alzheimer’s prevention while also providing cardiovascular benefits, positioning the company as a potential leader in addressing both neurodegenerative and cardiovascular diseases.

Executive/Board Changes
NewAmsterdam Pharma Updates Employment Agreement with Executive
Neutral
Jul 11, 2025

On July 11, 2025, NewAmsterdam Pharma B.V. updated its Employment Agreement with Dr. John Kastelein, effective July 1, 2025. This agreement outlines severance and benefits for Dr. Kastelein in cases of employment termination without cause or due to a change in control, impacting his stock options and equity awards.

Product-Related AnnouncementsPrivate Placements and FinancingBusiness Operations and Strategy
NewAmsterdam Pharma Schedules R&D Day for June 2025
Positive
Jun 11, 2025

NewAmsterdam Pharma Company announced a Research & Development Day event scheduled for June 11, 2025, in New York City, aimed at analysts and investors. The event will be webcast live, with a replay available for 30 days. The company has been active in clinical trials, with significant developments in its BROOKLYN, BROADWAY, and TANDEM Phase 3 studies, and has secured funding to support a potential U.S. commercial launch. The company’s product candidate, Obicetrapib, shows promise in addressing cardiometabolic diseases, and there are ongoing efforts to explore its therapeutic potential in Alzheimer’s disease and multi-infarct dementia.

Product-Related AnnouncementsBusiness Operations and Strategy
NewAmsterdam Pharma Announces Positive Phase 3 Trial Results
Positive
Jun 9, 2025

On June 9, 2025, NewAmsterdam Pharma announced positive topline data from their Phase 3 BROADWAY clinical trial, which evaluated the effects of obicetrapib on Alzheimer’s Disease biomarkers. The study showed statistically significant reductions in the primary outcome measure of p-tau217 in both the full study population and ApoE4 carriers, suggesting a potential preventive strategy for Alzheimer’s Disease. These findings highlight the potential of CETP inhibition in mitigating Alzheimer’s risk and further differentiate obicetrapib as a uniquely effective therapy addressing multiple health concerns, including cardiovascular and neurodegenerative diseases.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 09, 2025